Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. as the dominant mechanism involved in the rejection of allografts and tumors in animal models. Thus, attempts to develop effective immunotherapies in the human have emphasized the generation of T cells capable of recognizing antigens expressed by cancers. […]